SCHEMBL18368355

SCHEMBL18368355

CC(C)C1[C@H]2CN(C3COC3)C[C@@H]12

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAP3K12 Q12852 11/20 0.33
DLK1 P80370 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21859950 1.00 MAP3K12 (0.33) MAP3K12DLK1
SCHEMBL22098495 1.00 MAP3K12 (0.33) MAP3K12DLK1
SCHEMBL10119953 0.77 MAP3K12 (0.30) MAP3K12
SCHEMBL18379036 0.75
SCHEMBL20109897 0.75
SCHEMBL22991849 0.75
SCHEMBL17814859 0.75
SCHEMBL20115394 0.75
SCHEMBL18542742 0.73
SCHEMBL24086647 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3896064-A1 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS Gilead Sciences, Inc. (US) 2021-10-20 EP disclosed
US-11066414-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2021-07-20 US disclosed
US-20200123172-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2020-04-23 US disclosed
US-10577352-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2020-03-03 US disclosed
US-20190248807-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. (US) 2019-08-15 US disclosed
EP-3456717-A1 TABLETS CONTAINING 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CANCER GILEAD SCIENCES, INC. (US) 2019-03-20 EP disclosed
US-20190016705-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2019-01-17 US disclosed
US-9878995-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-01-30 US disclosed
US-9878995-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-01-30 US disclosed
US-20180002316-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2018-01-04 US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 US disclosed
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577352-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-20200123172-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-20180002316-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-20190016705-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-20190248807-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-11066414-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS MAP3K12 2435/4885DLK1 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.